Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477648 | 0.91 | CYP3A4 (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL749261 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL21854750 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12098768 | 0.87 | CYP3A4 (0.49) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12098800 | 0.86 | CYP3A4 (0.47) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12174987 | 0.85 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19521586 | 0.85 | CYP3A4 (0.65) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL9980235 | 0.84 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12098734 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL12098424 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140255344-A1 | Antiviral Compounds | Hiffmann-La Roche Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2766365-A1 | ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013095275-A1 | NOVEL HEPATITIS C VIRUS INHIBITORS | MEDIVIR AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013053657-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-18 | — | — | WO | disclosed |
| WO-2012123298-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CYP3A4 611/4885CYP2C9 1409/4885KCNH2 3883/4885 |
| US-20140255344-A1 | Antiviral Compounds | EIF2AK2, HAVCR2, MAVS | CYP3A4 146/4885CYP2C9 281/4885KCNH2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.